AI assistant
PLUS THERAPEUTICS, INC. — Director's Dealing 2011
Mar 1, 2011
34301_dirs_2011-03-01_84f49f71-0e8c-4add-a3b7-1079724461a3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2011-02-28
Reporting Person: HEDRICK MARC H (Director, President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-02-28 | Restricted Stock Award - Common Stock | A | 36850 | — | Acquired | 485088 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4000 | Indirect |
| Common Stock | 7800 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrant to Purchase Common Stock | $2.62 | 2014-05-12 | Common Stock (35000) | 35000 | Direct |
Footnotes
F1: The vesting of the Restricted Stock Award depends upon the achievement of certain performance goals for the year ended December 31, 2011. Those goals include obtaining certain FDA clearance or approval, achieving a targeted revenue increase and entering in to a major collaboration for development/commercialization of the Company's products. The deadline for achieving these goals is January 1, 2012, at which time the Compensation Committee will determine the percentage of stock that will continue to vest. The shares that continue to vest will be fully vested on Jan.1, 2013.